Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia
DOI:
https://doi.org/10.33192/Smj.2022.63Keywords:
Chronic phase chronic myeloid leukemia, epidemiology, diagnosis, treatment, monitoringAbstract
Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and BCR-ABL fusion oncogene. CML is one of the illnesses that may be treated using Tyrosine Kinase Inhibitors (TKIs), a type of targeted therapy. Since TKIs are the standard of therapy, long-term survival of CML has improved compared to chemotherapy and interferon-alpha. For the first-line treatment for CML, there are four commercially available TKIs that serve as an integral part of the disease management. However, there are many challenges in diagnosing, treating, and monitoring patients with chronic phase CML in Indonesia. This study highlights the epidemiology data of chronic phase CML patients, particularly at Dr. Cipto Mangunkusumo General Hospital, an Indonesian national referral hospital, and how to diagnose, select first-line TKIs, and monitor the response of treatment after TKIs administration.
References
Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic myeloid leukemia, version 2.2021. JNCCN J Natl Compr Cancer Netw. 2020;18(10):1385-415.
Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv41-51.
Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691-709.
Frazer R, Irvine AE, McMullin MF. Chronic myeloid leukaemia in the 21st century. Ulster Med J. 2007;76(1):8-17.
Jootar S. CML treatment in Asia-Pacific region. Hematology. 2012;17(Suppl 1):S72-4.
Weinschenker Bollmann P, Del Giglio A. Chronic myeloid leukemia: past, present, future. Einstein (Sao Paulo). 2011;9(2):236-43.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84.
Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89(1):14-23.
Reksodiputro A H. Epidemiology Study and Mutation Profile of Patients with Chronic Myeloid Leukemia (CML) in Indonesia. J Blood Disord Transfus. 2015;6(3):1-13.
Kuan JW, Michael MS. The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Med J Malaysia. 2018;73(2):78-85.
Rajabto W, Harryanto AR, Tadjoedin H, Harimurti K. Association of clinical features and hematological laboratories between Ph(+)/BCR-ABL (+) chronic myeloid leukemia and other type of Ph/BCR-ABL chronic myeloid leukemia. J Penyakit Dalam Indones. 2018;5(1):11-6.
Reksodiputro AH, Syafei S, Prayogo N, Karsono B, Rinaldi I, Rajabto W, et al. Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital. Acta Med Indones. 2010;42(1):2-5.
Schiffer CA. Diagnosis and treatment of chronic myeloid leukemia. Neoplast Dis Blood. 2018;90(10):49-68.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.
Tadjoedin H. Peran Mutasi Gen BCR-ABL pada Perjalanan Klinis Pasien Leukemia Granulositik Kronik (LGK): Kaitannya dengan Aspek Terapi Imatinib Mesylate (IM). Universitas Indonesia; 2015.
Rajabto W, Djianzonie JAC, Pratisthita LB, Shatri H. Priapismus as Leukostasis Manifestation in Chronic Myeloid Leukemia. Acta Med Indones. 2020;52(4):420-2.
Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol. 2020;191(2):171-93.
Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34(8):2138-49.
Do YR, Kwak JY, Kim JA, Kim HJ, Chung JS, Shin HJ, et al. Long-term data from a phase 3 study of radotinib versus Imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol. 2020;189(2):303-12.
Rabian F, Lengline E, Rea D. Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia. Curr Hematol Malig. 2019;14:492-500.
Rinaldi I, Reksodiputro AH, Jusman SW, Harahap A, Setiabudy R, Wanandi SI, et al. Longer hydroxyurea administration prior to imatinib mesylate is risk factor for unsuccessful major molecular response in chronic-phase chronic myeloid leukemia: Possibility of P-glycoprotein role. Asian Pacific J Cancer Prev. 2019;20(12):3689-95.
Sweet K. Chronic myeloid leukemia: Selecting First-line TKI Therapy. J Clin Outcomes Manag. 2019;26(3):131-41.
Marin D. Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia. Semin Hematol. 2010;47(4):312-8.
Russo D, Garcia-Gutierrez JV, Soverini S, Baccarani M. Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives. J Clin Med. 2020;9(6):1709.
Nesr G, Saleem Z, Arami S. Outcome of COVID-19 in patients with chronic myeloid leukemia: A single centre UK experience. J Med Virol 2022;94(4):1274-6.
Yılmaz U, Pekmezci A, Gül Y, Eşkazan AE. COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single- Center Survey from Turkey. Turk J Haematol. 2021;38(1):79-81. doi:10.4274/tjh.galenos.2020.2020.0472
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following conditions:
Copyright Transfer
In submitting a manuscript, the authors acknowledge that the work will become the copyrighted property of Siriraj Medical Journal upon publication.
License
Articles are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). This license allows for the sharing of the work for non-commercial purposes with proper attribution to the authors and the journal. However, it does not permit modifications or the creation of derivative works.
Sharing and Access
Authors are encouraged to share their article on their personal or institutional websites and through other non-commercial platforms. Doing so can increase readership and citations.
